

Feeling well. Living better.

Psoriatic Arthritis Referral Form

Publix Specialty Pharmacy (#3212)

7616 Southland Blvd, Suite 112
Orlando, FL 32809
Phone: 855-797-8254
Fax: 863-413-5723

Patient Information [Attach copy of front and back of prescription insurance card(s)]

Patient's First Name: _____ Patient's Last Name: _____ Date of Birth: ___/___/___ Male Female
Address: _____ City: _____ State: _____ Zip: _____
Primary Phone Number: (____) _____ Alt. Phone Number: (____) _____ Caregiver name: _____

Clinical Information [Attach copy of labs and office notes]

Diagnosis code(s): _____ Diagnosis: Psoriatic Arthritis (PsA) Psoriasis (PsO) Other: _____
Treatment status: New to therapy, previously denied by insurance: No Yes, include copy of denial letter Enroll in copay card/ bridge program if available and eligible: No Yes
 Continuation of therapy, start date: ___/___/___ Is the patient on samples? No Yes Weight: _____ kg lb, Height: _____ cm in
TB test results (within 6 months): N/A Negative Positive, Date of TB test: ___/___/___ Allergies: NKDA Other: _____
Prior therapy, reason for discontinuation, and treatment dates: _____

MEDICATION	DOSE/STRENGTH	DIRECTIONS	DISPENSE QTY	REFILLS
<input type="checkbox"/> Cimzia (certolizumab pegol)	<input type="checkbox"/> Starter Kit: 200 mg/mL PFS	Initial Dose: Inject 400 mg (2 x 200 mg) SC on days 1, 15, and 29	3 doses	0
	<input type="checkbox"/> 200 mg/mL PFS <input type="checkbox"/> 200 mg vial	Maintenance Dose: <input type="checkbox"/> Inject 400 mg (2 x 200 mg) SC every 4 weeks <input type="checkbox"/> Inject 200 mg SC every 2 weeks	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Cosentyx (secukinumab)	<input type="checkbox"/> 150 mg/mL Sensoready pen <input type="checkbox"/> 150 mg/mL PFS	Initial Dose: <input type="checkbox"/> Inject 150 mg SC once a week for 5 weeks (on days 1, 8, 15, 22, and 29)	56 days	0
		Maintenance Dose: <input type="checkbox"/> Inject 150 mg SC every 4 weeks <input type="checkbox"/> Inject 300 mg (2 x 150 mg) SC every 4 weeks	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> 50 mg/mL SureClick pen <input type="checkbox"/> 50 mg/mL PFS <input type="checkbox"/> 25 mg/0.5 mL PFS	<input type="checkbox"/> Inject 50 mg SC once a week <input type="checkbox"/> Other: _____	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
		<input type="checkbox"/> Humira (adalimumab)	<input type="checkbox"/> 40 mg pen <input type="checkbox"/> 40 mg PFS	<input type="checkbox"/> Inject 40 mg SC every 2 weeks <input type="checkbox"/> Other: _____
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> 125 mg/mL ClickJect pen <input type="checkbox"/> 125 mg/mL PFS	Inject 125 mg SC once a week	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
	<input type="checkbox"/> 250 mg vial (IV use only) Patient weight: _____	<input type="checkbox"/> Infuse _____ mg IV over 30 min x 1 dose, then within 24 hours start SC dosing <input type="checkbox"/> Infuse _____ mg IV over 30 min on days 1, 15, and 29 then every 4 weeks	1 dose <input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	0 _____
	Include: <input type="checkbox"/> Sterile water for inj 10 mL vial <input type="checkbox"/> Sodium chloride 0.9% inj 100 mL bag	Use 10 mL to reconstitute each 250 mg abatacept vial before dilution Dilute reconstituted abatacept to a final concentration of no more than 10 mg/mL	QS	_____
<input type="checkbox"/> Otezla (apremilast)	<input type="checkbox"/> Starter Pack: 55 tablets	Initial dose: Take as directed per package instructions	28 days	0
	<input type="checkbox"/> 30mg tablet	Maintenance dose: <input type="checkbox"/> Take 1 tab PO BID <input type="checkbox"/> Take 1 tab PO once a day (for severe renal impairment)	<input type="checkbox"/> 30 days <input type="checkbox"/> 90 days	_____
<input type="checkbox"/> Remicade (infliximab)	100 mg vial Patient weight: _____	Initial Dose: <input type="checkbox"/> Infuse _____ mg (____ mg/kg) IV over at least 2 hours on days 1, 15, and 43	3 doses	0
		Maintenance Dose: <input type="checkbox"/> Infuse _____ mg (____ mg/kg) IV over at least 2 hours every 8 weeks	56 days	_____
<input type="checkbox"/> Renflexis (infliximab-abda)	Include: <input type="checkbox"/> Sterile water for inj 10 mL vial <input type="checkbox"/> Sodium chloride 0.9% inj 250 mL bag	Use 10 mL to reconstitute each 100 mg infliximab vial before dilution Dilute reconstituted infliximab to a final concentration of 0.4 to 4 mg/mL	QS	_____
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 50 mg/0.5 mL SmartJect pen <input type="checkbox"/> 50 mg/0.5 mL PFS	Inject 50 mg SC every 4 weeks	<input type="checkbox"/> 28 days <input type="checkbox"/> 84 days	_____
		<input type="checkbox"/> Stelara (ustekinumab)	45 mg/0.5 mL PFS	Initial Dose: <input type="checkbox"/> Inject 45 mg SC on day 1, then 4 weeks later on day 29
			<input type="checkbox"/> Maintenance Dose: Inject 45 mg SC every 12 weeks	84 days

Prescriber Information [Ship to prescriber: Never Always First fill only, appointment date: ___/___/___] Use Cover My Meds: No Yes

Name: _____ DEA# _____ NPI # _____
Address: _____ City: _____ State: _____ Zip: _____
Office Phone Number: (____) _____ Fax Number: (____) _____ Office Contact: _____

I authorize Publix Pharmacy representatives to act on behalf of the prescriber to initiate and complete the insurance prior authorization process.

Prescriber's signature: _____
(stamps not accepted) Substitution allowed Date Dispense as written/ Do not substitute Date

For states requiring hand written expressions to prevent substitution, write here:

This document, and any attachments, are intended solely for the use of the individual(s) to whom they are addressed. They may contain confidential information and/or protected health information (PHI) that is protected by law. If you believe you were not the intended recipient of this document, you are hereby notified that any review, dissemination, distribution, printing or copying of this document and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and destroy this document and any attachments. If you properly received this document, you should maintain its contents in confidence in accordance with applicable law.